Leap Therapeutics, Inc.

NasdaqCM LPTX

Leap Therapeutics, Inc. Market Capitalization on January 14, 2025: USD 118.40 M

Leap Therapeutics, Inc. Market Capitalization is USD 118.40 M on January 14, 2025, a 35.84% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

Leap Therapeutics, Inc. 52-week high Market Capitalization is USD 167.70 M on October 29, 2024, which is 41.64% above the current Market Capitalization.
Leap Therapeutics, Inc. 52-week low Market Capitalization is USD 53.75 M on March 18, 2024, which is -54.60% below the current Market Capitalization.
Leap Therapeutics, Inc. average Market Capitalization for the last 52 weeks is USD 93.87 M.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

NasdaqCM: LPTX

Leap Therapeutics, Inc.

CEO	Mr. Douglas E. Onsi J.D.
IPO Date	Jan. 25, 2017
Location	United States
Headquarters	47 Thorndike Street
Employees	54
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Key trends

Past 5 years